Related Experiment Video

Updated: Jun 16, 2026

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
09:38

A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time

Published on: February 14, 2017

Platelet proinflammatory activity in clinically stable patients with CF starts in early childhood

Alexander Sturm1, Helge Hebestreit, Corinne Koenig

  • 1University Children's Hospital, 97080 Würzburg, Germany.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|February 16, 2010
PubMed

Insights

Platelets show increased inflammatory activity in cystic fibrosis (CF) patients from a young age, potentially worsening inflammation and tissue damage. However, their ability to form clots appears reduced in active CF inflammation.

Area of Science:

  • Hematology
  • Immunology
  • Pulmonology

Background:

  • Chronic inflammation is a hallmark of cystic fibrosis (CF).
  • Platelets are implicated in inflammatory processes through cytokine release and leukocyte interactions.

Purpose of the Study:

  • To investigate platelet proinflammatory and procoagulatory functions in CF patients.
  • To assess how inflammation and age affect platelet function in CF.

Main Methods:

  • Measured soluble CD62P, soluble CD40L, platelet-leukocyte aggregates, and platelet CD62P.
  • Assessed PAC-1 binding to activated integrin alpha(IIb)beta(3) and CD41a expression.

Main Results:

  • Elevated soluble CD62P and soluble CD40L in CF patients, independent of age or inflammation activity.
  • Increased platelet-leukocyte aggregates in older CF patients.
  • Reduced PAC-1 binding and CD41a exocytosis upon platelet activation in CF patients with active inflammation.

Conclusions:

  • Platelets exhibit heightened proinflammatory activity in young CF patients, potentially contributing to inflammation and tissue damage.
  • Platelet integrin alpha(IIb)beta(3) activation for clot formation is downregulated in CF, especially during active inflammation.
Abstract

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Inflammation01:38

Inflammation

Overview
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...